This year’s event will focus on the pre-clinical entities that are crucial when moving forward in clinical trials. This will include, assessing antigen discovery and genome sequencing in addition to evaluating biomarkers and chimeric antigen receptors.
There is a growing demand for combination therapies and assessing clinical trial design, especially with failures in the clinic increasing, the question to be asked is how can we learn from this and move forward to ensure phase III developments and regulatory approval?
The agenda will focus on in vivo targeting of antigens to dendritic cells for therapeutic anti-cancer vaccines, reviewing preventive vaccine novel adjuvants programmes aswell as evaluating patient stratification.
Furthermore, it will enable a broad range of academics, small biotechs and large pharmaceutical companies to reviewanalytical methods to enable reliability upon standardisation of assays. In addition to assessing the modulation of the tumour microenvironment within early stages of their research and development.
- Activated Allogenec Dcs as an Off-the-shelf Vaccine Adjuvant in Cancer Immunotherapy
- Assessing the Developments in the Field of Cancer Vaccines
- Cancer Vaccination in the Era of Immunomodulatory Immunotherapy
- Case Study: Oncolytic Vaccines — a Step into Cancer Immunotherapy
- Phase I/ii Trial of a Novel Antibody Dna Immunotherapy, Scib1 Immunobody Which Targets Cd64, in the Treatment of Melanoma
- Therapeutic Vaccines for the Treatment of Cancer — Where Are We Now?
- T-cell Immune Monitoring: Reliability, Standardisation and Use in Clinical Trials
- T-vec – Oncolytic Immunotherapy in Metastatic Melanoma
- A Perfect Partnership — a University of Pennsylvania and Novartis Collaboration!
- Assessing Regulatory Approval and Clinical Trial Design
- Biomarker-guided Development of Novel Cancer Vaccines– from Off-the-shelf to Actively Personalised
- Head and Neck Cancer Immunotherapy: Translating Laboratory Science into a Clinical Program
- High Expectations and Harnessing the Body’s Immune System
- Proactive Issue of Tumor Genomic Heterogeneity in Immunotherapy
- Rnactive® for Cancer Immunotherapy
- What Are the Key Questions in Cancer Immunotherapy
- Alex Karlsson-Parra – CSO, Immunicum AB
- Birgit Scheel – Director Program Management Oncology, Curevac GmbH
- Christian Ottensmeier – Professor in Experimental Cancer Medicine, University Of Southampton, United Kingdom
- Emma King – CRUK Senior Lecturer in Head and Neck Surgery, Southampton University, United Kingdom
- Harpreet Singh – Managing Director, Founder and CSO, Immatics Biotechnologies GmbH
- John Beadle – Chief Executive Officer, Psioxus Therapeutics
- Joseph Melenhorst – Director of the Product Development & Correlative Sciences Laboratory, University Of Pennsylvania, United States
- Liselotte Brix – COO, Immudex
- Madiha Derouazi – CEO Amal Therapeutics
- Tom Lillie – Therapeutic Area Head, Oncology, Amgen Ltd
Benefits of Attending
- An excellent starting point for worldwide benchmarking
- Hear the latest regulatory insight into market approval and clinical trial design
- Evaluate case studies from leading academics and industry professionals
- Assess Strategies to enable positive developments in the field of Cancer Vaccines
How should attend?
- Professor of Oncology
- Professor of Immunochemistry
- Professor of Cancer Medicine and Medicinal Oncology
- Professor of Experimental Immunology
- Director of Immunopharmacology
- Medical Assessor, Biologics Licensing
- Scientist, Tumour Immunology
- Head of Clinical Analysis
- Director of Research
- Consultant in Medical Oncology
- Head of Immunology